Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 14/20 | 0.71 |
| ▸ | PDE4A | P27815 | 7/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5257428 | 0.98 | CYP2C9 (0.75) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5255104 | 0.90 | CYP2C9 (0.77) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4204624 | 0.89 | CYP2C9 (0.66) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4204741 | 0.85 | CYP2C9 (0.87) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4207488 | 0.84 | CYP2C9 (0.60) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4037953 | 0.84 | CYP2C9 (0.74) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4208966 | 0.84 | CYP2C9 (0.78) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4207515 | 0.84 | CYP2C9 (0.85) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4211422 | 0.84 | CYP2C9 (0.74) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5254871 | 0.84 | CYP2C9 (0.67) | CYP2C9PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563807-B2 | Removal of aldehyde impurity by reactive polystyrene resini | MERCK & CO. INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563807-B2 | Removal of aldehyde impurity by reactive polystyrene resini | MERCK & CO. INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1487797-B1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-05-27 | — | — | EP | disclosed |
| EP-1363635-B1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7482456-B2 | antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol | MERCK FROSST CANADA | 2009-01-27 | — | — | US | disclosed |
| EP-1517895-B1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-03-14 | — | — | EP | disclosed |
| US-20070054941-A1 | Removal of aldehyde impurity by reactive polystyrene resini | MERCK SHARP & DOHME CORP. | 2007-03-08 | — | — | US | disclosed |
| US-20070054941-A1 | Removal of aldehyde impurity by reactive polystyrene resini | MERCK SHARP & DOHME CORP. | 2007-03-08 | — | — | US | disclosed |
| US-7153968-B2 | 8-(biaryl)quinoline PDE4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2006-12-26 | — | — | US | disclosed |
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
| US-6740666-B2 | FOR THERAPY OF ASTHMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, EOSINOPHILIC GRANULOMA, PSORIASIS; SEPTIC SHOCK, ULCERATIVE COLITIS, CROHN'S DISEASE, REPERFUSION INJURY OF THE MYOCARDIUM AND BRAIN, INFLAMMATION | MERCK & CO., INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1404330-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-04-07 | — | — | EP | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003078397-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-10-03 | — | — | US | disclosed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | disclosed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | PDE12, PDE4A, PDE4B | CYP2C9 712/4885PDE4A 2/4885PDE4B 3/4885 |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | CYP2C9 976/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | CYP2C9 381/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20070054941-A1 | Removal of aldehyde impurity by reactive polystyrene resini | ALDH1A1, ALDH1A2, ALDH3A1 | CYP2C9 3264/4885PDE4A 3191/4885PDE4B 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.